ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2021
The SARS-CoV-2 B.1.351 lineage (VOC β) is outgrowing the B.1.1.7 lineage (VOC α) in some French regions in April 2021.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Data-driven mechanistic framework with stratified immunity and effective transmissibility for COVID-19 scenario projections.Epidemics · 2024Article
- Real-time forecasting of COVID-19-related hospital strain in France using a non-Markovian mechanistic model.PLoS computational biology · 2024Article
- Article
- Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases.Cell communication and signaling : CCS · 2023Review
- The use of representative community samples to assess SARS-CoV-2 lineage competition: Alpha outcompetes Beta and wild-type in England from January to March 2021.Microbial genomics · 2023Article
- SARS-CoV-2 variants and vulnerability at the global level.Journal of medical virology · 2022Review
- SARS-CoV-2: phenotype, genotype, and characterization of different variants.Cellular & molecular biology letters · 2022Article
- Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences.Vaccines · 2022Review
- Selection for infectivity profiles in slow and fast epidemics, and the rise of SARS-CoV-2 variants.eLife · 2022Article
- A tentative assessment of the changes in transmissibility and fatality risk associated with Beta SARS-CoV-2 variants in South Africa: an ecological study.Pathogens and global health · 2022Article
- Comparison of three molecular diagnostic assays for SARS-CoV-2 detection: Evaluation of analytical sensitivity and clinical performance.Journal of clinical laboratory analysis · 2022Article
- Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection.Journal of biomedical science · 2022Review
- Novel Lateral Flow-Based Assay for Simple and Visual Detection of SARS-CoV-2 Mutations.Frontiers in cellular and infection microbiology · 2022Article
- Review
- SARS-CoV-2 B.1.1.7 Decline Is Not Driven by the Introduction of a More Successful Variant.Microbiology spectrum · 2021Article
- Genomic Epidemiology of SARS-CoV-2 Divulge B.1, B.1.36, and B.1.1.7 as the Most Dominant Lineages in First, Second, and Third Wave of SARS-CoV-2 Infections in Pakistan.Microorganisms · 2021Article
- Possible future waves of SARS-CoV-2 infection generated by variants of concern with a range of characteristics.Nature communications · 2021Article
- Rapid spread of the SARS-CoV-2 Delta variant in some French regions, June 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
- Characterization of SARS-CoV-2 Variants N501Y.V1 and N501Y.V2 Spike on Viral Infectivity.Frontiers in cellular and infection microbiology · 2021Article
- The co-circulating transmission dynamics of SARS-CoV-2 Alpha and Eta variants in Nigeria: A retrospective modeling study of COVID-19.Journal of global health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To assess SARS-CoV-2 variants spread, we analysed 36,590 variant-specific reverse-transcription-PCR tests performed on samples from 12 April-7 May 2021 in France. In this period, contrarily to January-March 2021, variants of concern (VOC) β (B.1.351 lineage) and/or γ (P.1 lineage) had a significant transmission advantage over VOC α (B.1.1.7 lineage) in Île-de-France (15.8%; 95% confidence interval (CI): 15.5-16.2) and Hauts-de-France (17.3%; 95% CI: 15.9-18.7) regions. This is consistent with VOC β's immune evasion abilities and high proportions of prior-SARS-CoV-2-infected persons in these regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.